• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Bio-Rad Appoints Jon DiVincenzo President, Chief Operating Officer

    8/20/24 8:30:00 AM ET
    $BIO
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Get the next $BIO alert in real time by email

    Bio-Rad Laboratories, Inc. (NYSE:BIO), a global leader in life science research and clinical diagnostics products, today announced that Jon DiVincenzo will join the company as President and Chief Operating Officer, effective September 9, 2024, replacing Andy Last, who is retiring.

    Mr. DiVincenzo joins Bio-Rad from Labcorp Holdings Inc., a global provider of comprehensive laboratory services, where he held various global operational and commercial leadership roles across the company's several business units. Most recently, he served as Executive Vice President and President, Central Laboratories and International. Prior to LabCorp, Mr. DiVincenzo was President of the Environmental Health Division at PerkinElmer, a global company focused on diagnostics, life science research, food quality, environmental health and industrial testing. He also served as Chief Executive Officer of Enzymatics, a privately held molecular biology reagents company. Prior to that, Mr. DiVincenzo held roles of increasing responsibility in the Biosciences and Lab Water businesses of EMD Millipore, a subsidiary of Merck KGaA. He holds a Bachelor of Science degree in mechanical engineering from Northeastern University.

    "We are thrilled to welcome Jon DiVincenzo as our President and Chief Operating Officer," stated Norman Schwartz, Bio-Rad's Chairman and Chief Executive Officer. "Jon brings to Bio-Rad over thirty years of industry experience across strategic, operational, and commercial organizations in both life science and clinical diagnostics. His extensive track record spans leadership roles in operations, marketing, and product development, which will be integral to our continued success."

    Mr. DiVincenzo stated, "I am excited to join Bio-Rad and I look forward to working with the executive team to continue to make progress towards achieving the company's long-term transformational and growth objectives."

    About Bio-Rad

    Bio-Rad Laboratories, Inc. (NYSE:BIO) is a leader in developing, manufacturing, and marketing a broad range of products for the life science research and clinical diagnostics markets. Based in Hercules, California, Bio-Rad operates a global network of research, development, manufacturing, and sales operations with over 7,700 employees, and $2.7 billion in revenues in 2023. Our customers include universities, research institutions, hospitals, food safety and environmental quality laboratories, and biopharmaceutical companies. Together, we develop innovative, high-quality products that advance science and save lives. To learn more, visit bio-rad.com.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20240820682671/en/

    Get the next $BIO alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BIO

    DatePrice TargetRatingAnalyst
    10/1/2024$350.00 → $400.00Neutral → Buy
    Citigroup
    8/28/2024$340.00Equal Weight
    Wells Fargo
    6/3/2024$315.00Hold
    Jefferies
    4/3/2024$400.00 → $365.00Buy → Neutral
    Citigroup
    12/7/2023$395.00Buy
    UBS
    6/16/2023$550.00Overweight
    Wells Fargo
    12/7/2022$565.00Outperform
    RBC Capital Mkts
    8/25/2022$715.00Outperform
    Credit Suisse
    More analyst ratings

    $BIO
    SEC Filings

    View All

    Bio-Rad Laboratories, Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits

    8-K - BIO-RAD LABORATORIES, INC. (0000012208) (Filer)

    11/18/21 4:46:00 PM ET
    $BIO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form 10-Q filed by Bio-Rad Laboratories, Inc.

    10-Q - BIO-RAD LABORATORIES, INC. (0000012208) (Filer)

    10/29/21 4:06:54 PM ET
    $BIO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Bio-Rad Laboratories, Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - BIO-RAD LABORATORIES, INC. (0000012208) (Filer)

    10/28/21 4:27:41 PM ET
    $BIO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $BIO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3: New insider May Simon claimed ownership of 43 units of Bio-Rad A Common Stock

    3 - BIO-RAD LABORATORIES, INC. (0000012208) (Issuer)

    1/7/22 1:09:06 PM ET
    $BIO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form 4: Wright Dara converted options into 502 units of Bio-Rad A Common Stock and covered exercise/tax liability with 221 units of Bio-Rad A Common Stock, increasing direct ownership by 46% to 892 units

    4 - BIO-RAD LABORATORIES, INC. (0000012208) (Issuer)

    12/17/21 2:21:01 PM ET
    $BIO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form 4: Schwartz Norman D received a gift of 40 units of Bio-Rad B Common Stock, increasing direct ownership by 0.01% to 316,146 units

    4 - BIO-RAD LABORATORIES, INC. (0000012208) (Issuer)

    11/23/21 2:30:23 PM ET
    $BIO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $BIO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Bio-Rad to Host Droplet Digital PCR Webinar on Tuesday, August 26, 2025

    Bio-Rad Laboratories, Inc. (NYSE:BIO), a global leader in life science research and clinical diagnostics products, announced today that the company's management will host an informational webinar on Bio-Rad's Droplet Digital™ PCR (ddPCR™) product portfolio on Tuesday, August 26, 2025, at 10:00 AM Pacific Time (1:00 PM Eastern Time). The event will include a presentation followed by a Q&A session with analysts hosted by Bio-Rad's President and Chief Operating Officer Jon DiVincenzo and Chief Financial Officer Roop K. Lakkaraju. To participate, dial (800) 715-9871 within the U.S. or (+1) (646) 307-1963 outside the U.S., access code: 9562470. A live webcast of the event, and the accompanying

    8/1/25 9:00:00 AM ET
    $BIO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Bio-Rad Reports Second-Quarter 2025 Financial Results

    Bio-Rad Laboratories, Inc. (NYSE:BIO), a global leader in life science research and clinical diagnostics products, today announced financial results for the second quarter ended June 30, 2025. Norman Schwartz, Bio-Rad's Chairman and Chief Executive Officer, stated: "In a highly dynamic environment, we delivered solid quarterly results, both in terms of revenue and operating margin, through focused execution and careful expense management. We also completed the acquisition of droplet digital PCR developer Stilla Technologies, effectively expanding our Droplet Digital™ PCR offering with the recent launch of our QX Continuum™ system complemented by the QX700™ series of acquired instruments."

    7/31/25 4:15:00 PM ET
    $BIO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Bio-Rad Appoints Rajat Mehta Executive Vice President, Global Commercial Operations

    Bio-Rad Laboratories, Inc. (NYSE:BIO), a global leader in life science research and clinical diagnostics products, today announced the appointment of Rajat Mehta as its new Executive Vice President, Global Commercial Operations, effective August 4, 2025. Mehta will lead Bio-Rad's global commercial strategy and execution, succeeding Mike Crowley, who is retiring after a distinguished 26-year career with the company. Mehta brings extensive leadership and commercial expertise in biopharmaceutical, life science research, and diagnostics markets to Bio-Rad. He joins from Labcorp, where he served as Senior Vice President, overseeing large-scale commercial operations for the company's West Divis

    7/28/25 4:15:00 PM ET
    $BIO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $BIO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Bio-Rad Labs upgraded by Citigroup with a new price target

    Citigroup upgraded Bio-Rad Labs from Neutral to Buy and set a new price target of $400.00 from $350.00 previously

    10/1/24 7:11:23 AM ET
    $BIO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Wells Fargo initiated coverage on Bio-Rad Labs with a new price target

    Wells Fargo initiated coverage of Bio-Rad Labs with a rating of Equal Weight and set a new price target of $340.00

    8/28/24 7:34:48 AM ET
    $BIO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Jefferies resumed coverage on Bio-Rad Labs with a new price target

    Jefferies resumed coverage of Bio-Rad Labs with a rating of Hold and set a new price target of $315.00

    6/3/24 8:40:37 AM ET
    $BIO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $BIO
    Leadership Updates

    Live Leadership Updates

    View All

    Bio-Rad Appoints Rajat Mehta Executive Vice President, Global Commercial Operations

    Bio-Rad Laboratories, Inc. (NYSE:BIO), a global leader in life science research and clinical diagnostics products, today announced the appointment of Rajat Mehta as its new Executive Vice President, Global Commercial Operations, effective August 4, 2025. Mehta will lead Bio-Rad's global commercial strategy and execution, succeeding Mike Crowley, who is retiring after a distinguished 26-year career with the company. Mehta brings extensive leadership and commercial expertise in biopharmaceutical, life science research, and diagnostics markets to Bio-Rad. He joins from Labcorp, where he served as Senior Vice President, overseeing large-scale commercial operations for the company's West Divis

    7/28/25 4:15:00 PM ET
    $BIO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Palantir Technologies, Dell Technologies, and Erie Indemnity Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600

    NEW YORK, Sept. 6, 2024 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") will make the following changes to the S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open of trading on Monday, September 23, to coincide with the quarterly rebalance. The changes ensure each index is more representative of its market capitalization range. All companies being added to the S&P 500 are more representative of the large-cap market space, all companies being added to the S&P MidCap 400 are more representative of the mid-cap market space, and all companies being added to the S&P SmallCap 600 are more representative of the small-cap market space. The companies being removed from

    9/6/24 6:43:00 PM ET
    $AAL
    $ADMA
    $ADNT
    Air Freight/Delivery Services
    Consumer Discretionary
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Bio-Rad Appoints Jon DiVincenzo President, Chief Operating Officer

    Bio-Rad Laboratories, Inc. (NYSE:BIO), a global leader in life science research and clinical diagnostics products, today announced that Jon DiVincenzo will join the company as President and Chief Operating Officer, effective September 9, 2024, replacing Andy Last, who is retiring. Mr. DiVincenzo joins Bio-Rad from Labcorp Holdings Inc., a global provider of comprehensive laboratory services, where he held various global operational and commercial leadership roles across the company's several business units. Most recently, he served as Executive Vice President and President, Central Laboratories and International. Prior to LabCorp, Mr. DiVincenzo was President of the Environmental Health D

    8/20/24 8:30:00 AM ET
    $BIO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $BIO
    Financials

    Live finance-specific insights

    View All

    Bio-Rad Reports Second-Quarter 2025 Financial Results

    Bio-Rad Laboratories, Inc. (NYSE:BIO), a global leader in life science research and clinical diagnostics products, today announced financial results for the second quarter ended June 30, 2025. Norman Schwartz, Bio-Rad's Chairman and Chief Executive Officer, stated: "In a highly dynamic environment, we delivered solid quarterly results, both in terms of revenue and operating margin, through focused execution and careful expense management. We also completed the acquisition of droplet digital PCR developer Stilla Technologies, effectively expanding our Droplet Digital™ PCR offering with the recent launch of our QX Continuum™ system complemented by the QX700™ series of acquired instruments."

    7/31/25 4:15:00 PM ET
    $BIO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Bio-Rad to Report Second Quarter 2025 Financial Results on Thursday, July 31, 2025

    Bio-Rad Laboratories, Inc. (NYSE:BIO), a global leader in life science research and clinical diagnostics products, will report its financial results for the second quarter of 2025 on Thursday, July 31, 2025, following the close of the market. Management will discuss these results in a conference call scheduled for 2:00 PM Pacific Time (5:00 PM Eastern Time) that day. To participate, dial (800) 715-9871 within the U.S. or (646) 307-1963 outside the U.S., access code: 9562470. A live webcast of the conference call, as well as a supplemental earnings presentation, will also be available in the "Investor Relations" section of the company's website under "Events & Presentations" at investors.b

    7/17/25 4:15:00 PM ET
    $BIO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Bio-Rad Reports First-Quarter 2025 Financial Results

    Bio-Rad Laboratories, Inc. (NYSE:BIO), a global leader in life science research and clinical diagnostics products, today announced financial results for the first quarter ended March 31, 2025. Norman Schwartz, Bio-Rad's Chairman and Chief Executive Officer, stated: "We navigated a highly dynamic first quarter that became progressively more challenging, yet we delivered solid margins through focused execution and careful expense management. Given the current levels of market uncertainty, we are moderating our full-year 2025 outlook to reflect the evolving macro environment. Going forward, we remain committed to advancing our growth and margin expansion initiatives." Financial Results Highl

    5/1/25 4:15:00 PM ET
    $BIO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $BIO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed

    SC 13G/A - BIO-RAD LABORATORIES, INC. (0000012208) (Subject)

    2/10/21 10:39:36 AM ET
    $BIO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form SC 13G filed

    SC 13G - BIO-RAD LABORATORIES, INC. (0000012208) (Subject)

    2/8/21 10:17:35 AM ET
    $BIO
    Biotechnology: Laboratory Analytical Instruments
    Industrials